As a result of recent advances in imaging and biofluid analysis, diagnosis in Alzheimer’s disease is moving toward a biological definition.69 Assays have been developed to detect abnormal alpha-synuclein in skin, cerebrospinal fluid (CSF), and blood,70–72 although the development of alpha-synuclein imaging ligands is less advanced.73 A widely available, sensitive and specific test for synucleinopathy would revolutionize the in-vivo diagnosis of LB disease at all clinical stages and would represent a significant advance for the field. Here, SNCA is linked to synucleinopathy.